Thomas D. Nolin, PharmD ’99, PhD ’03, chaired an inaugural Kidney Health Initiative (KHI) workgroup to propose recommendations for the standardized assessment of pharmacokinetics and development of corresponding drug dosing recommendations in critically ill patients with acute kidney injury receiving continuous renal replacement therapy.
The KHI is a formal public-private partnership founded in 2012 by the American Society of Nephrology and the U.S. Food and Drug Administration (FDA). The workgroup was composed of clinicians and scientists representing FDA, academia, and pharmaceutical and dialysis industries. The workgroup’s recommendations were published in the September 2014 issue of the Clinical Journal of the American Society of Nephrology. In addition, the workgroup organized an open workshop on November 11, 2014 titled Standardized Pharmacokinetics Assessment in Patients Receiving Continuous Renal Replacement Therapy to present the recommendations in a public forum to primary stakeholders. The published recommendations and the workshop agenda may be found The American Society of Nephrology (ASN) Kidney Health Initiatives (KHI)
Nolin is an assistant professor in the department of pharmacy and therapeutics and member of the Center for Clinical Pharmaceutical Sciences at the School of Pharmacy.
Pingback: Kidney Health Initiative 2015 | How to Cure Kidney Disease